| |
|
|
|
Nymox Pharmaceutical Corporation  
|
|
1.78 0.05 (0.03%) |
10-18 16:00 |
|
Open: |
1.73 |
Pre close: |
1.73 |
Target:
|
2.34 
|
|
High: |
1.8 |
Low: |
1.71 |
Resistance:
|
2.01
2.19
|
|
Volume: |
45,102 |
Market Cap: |
124M |
Support:
|
1.71
1.42
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.84
|
MACD |
MACD(12,26):
|
-0.00 |
|
MA(20): |
1.91 |
Signal(12,26,9): |
0.02 |
|
MA(100): |
1.74 |
Stochastic Oscillator |
%K(14,3):
|
12.79 |
|
MA(250): |
1.85  |
%D(3): |
21.42 |
|
Average Volume(K) |
3-Month: |
5995
|
52-Week |
High:
|
2.75 |
|
10-Days: |
7285 |
Low: |
1.25 |
|
RSI |
RSI(14):
|
42.88 |
Change(%): |
5.3 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.207 |
Return on Equity (ttm) |
-243.3 |
Shares Out. (M) |
69.72 |
|
EPS Est. Current Year |
-0.200 |
Return on Assets (ttm) |
-116.5 |
Shares Float (M) |
39.43 |
|
EPS Est. Next Year |
-0.570 |
PEG Ratio |
0.00 |
% Held by Insiders |
41.49 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
-77.3 |
% Held by Institutions |
6.37 |
|
Forward EPS |
1.#IO |
Gross Profit (p.s.) |
0.002 |
Shares Short (K) |
1280 |
|
Book Value (p.s.) |
0.110 |
EBITDA (p.s.) |
-0.196 |
P/E |
-8.60 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
16.18 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-7.78 |
P/S |
0.00 |
|
Operating Margin |
-12674.07 |
Levered Free Cash Flow
(M) |
-3.14 |
P/CF |
-15.95 |
|
|
|
|
|
|
